[
  {
    "ts": null,
    "headline": "Why AbbVie Stock Trounced the Market Today",
    "summary": "Of the two notes, arguably the more impactful was the one BMO Capital's Evan David Seigerman published before market open.  The analyst continues to be positive on AbbVie, as he maintained his outperform (buy, in other words) recommendation on the stock and $215 per-share price target.  Not surprisingly, according to reports, Seigerman focused on AbbVie's first-quarter earnings release that was published on Friday.",
    "url": "https://finnhub.io/api/news?id=0ffb8fe397763cf0388f09338d1c1301d9fb9968042d340e229d7f0055facaa2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745881320,
      "headline": "Why AbbVie Stock Trounced the Market Today",
      "id": 134130974,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Of the two notes, arguably the more impactful was the one BMO Capital's Evan David Seigerman published before market open.  The analyst continues to be positive on AbbVie, as he maintained his outperform (buy, in other words) recommendation on the stock and $215 per-share price target.  Not surprisingly, according to reports, Seigerman focused on AbbVie's first-quarter earnings release that was published on Friday.",
      "url": "https://finnhub.io/api/news?id=0ffb8fe397763cf0388f09338d1c1301d9fb9968042d340e229d7f0055facaa2"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Gains and Losses Today: AbbVie Stock Advances After Beat-and-Raise Earnings Report",
    "summary": "The S&P 500 edged 0.1% higher on Monday, April 28, eking out a fifth straight winning session to kick off a week of key earnings reports and economic data releases.",
    "url": "https://finnhub.io/api/news?id=f19e58831e9b57c90b555f84325ec71c09579d5e3f21dcc8387f95168127b0db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745874474,
      "headline": "S&P 500 Gains and Losses Today: AbbVie Stock Advances After Beat-and-Raise Earnings Report",
      "id": 134130975,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The S&P 500 edged 0.1% higher on Monday, April 28, eking out a fifth straight winning session to kick off a week of key earnings reports and economic data releases.",
      "url": "https://finnhub.io/api/news?id=f19e58831e9b57c90b555f84325ec71c09579d5e3f21dcc8387f95168127b0db"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=d08b92e8f9f040884f053538554558b9d39aea1be9d7266732326c87200a7c97",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745857800,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 134127437,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=d08b92e8f9f040884f053538554558b9d39aea1be9d7266732326c87200a7c97"
    }
  },
  {
    "ts": null,
    "headline": "ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials",
    "summary": "Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other anti-cancer antibodies.",
    "url": "https://finnhub.io/api/news?id=9182b43072a6ccffd587317e8378ee071ccf66c303203025f533acac5f3d3a80",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745841073,
      "headline": "ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials",
      "id": 134115092,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other anti-cancer antibodies.",
      "url": "https://finnhub.io/api/news?id=9182b43072a6ccffd587317e8378ee071ccf66c303203025f533acac5f3d3a80"
    }
  },
  {
    "ts": null,
    "headline": "3 Dividend Stocks to Buy and Hold for the Next Decade",
    "summary": "Three Motley Fool contributors believe they've identified fantastic dividend stocks to buy and hold for the next decade.  Here's why they chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Pfizer (NYSE: PFE).",
    "url": "https://finnhub.io/api/news?id=f01ba2d3ec3d103af1c134fd9efc60336bacfb9b7cb29f03b3d41a2a0535ef96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745840820,
      "headline": "3 Dividend Stocks to Buy and Hold for the Next Decade",
      "id": 134115093,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Three Motley Fool contributors believe they've identified fantastic dividend stocks to buy and hold for the next decade.  Here's why they chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Pfizer (NYSE: PFE).",
      "url": "https://finnhub.io/api/news?id=f01ba2d3ec3d103af1c134fd9efc60336bacfb9b7cb29f03b3d41a2a0535ef96"
    }
  },
  {
    "ts": null,
    "headline": "Company News for Apr 28, 2025",
    "summary": "Companies In The News Are: ABBV, SLB, CL, CHTR.",
    "url": "https://finnhub.io/api/news?id=c0d747804c8403f308338e3cc4003c5c805cd80c63c4aa7d06ef6f85f45e1c35",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745831880,
      "headline": "Company News for Apr 28, 2025",
      "id": 134115094,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Companies In The News Are: ABBV, SLB, CL, CHTR.",
      "url": "https://finnhub.io/api/news?id=c0d747804c8403f308338e3cc4003c5c805cd80c63c4aa7d06ef6f85f45e1c35"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts",
    "summary": "AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts",
    "url": "https://finnhub.io/api/news?id=ebf9493393669f05ccd596a6bad377d5588d67247f3c9382a1cc7899b56d92c5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745829840,
      "headline": "AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts",
      "id": 134146977,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts",
      "url": "https://finnhub.io/api/news?id=ebf9493393669f05ccd596a6bad377d5588d67247f3c9382a1cc7899b56d92c5"
    }
  },
  {
    "ts": null,
    "headline": "Should Investors Be Worried About Dividend King AbbVie?",
    "summary": "Nearly everything looked great with AbbVie's (NYSE: ABBV) first-quarter results.  AbbVie beat Wall Street's top- and bottom-line estimates.  Should investors be worried about this healthcare Dividend King?",
    "url": "https://finnhub.io/api/news?id=c539d0cdc14637f83e3c263f96297da6eb6d9a56a026091a7a06bac2bc234897",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745829720,
      "headline": "Should Investors Be Worried About Dividend King AbbVie?",
      "id": 134115095,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Nearly everything looked great with AbbVie's (NYSE: ABBV) first-quarter results.  AbbVie beat Wall Street's top- and bottom-line estimates.  Should investors be worried about this healthcare Dividend King?",
      "url": "https://finnhub.io/api/news?id=c539d0cdc14637f83e3c263f96297da6eb6d9a56a026091a7a06bac2bc234897"
    }
  },
  {
    "ts": null,
    "headline": "Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV",
    "summary": "NEW YORK, April 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. . ...",
    "url": "https://finnhub.io/api/news?id=91e1f9c433b1bcce07724ce70aed3ac6993b4affa87272b58348fee031bf3618",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745819178,
      "headline": "Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV",
      "id": 134112561,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "NEW YORK, April 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. . ...",
      "url": "https://finnhub.io/api/news?id=91e1f9c433b1bcce07724ce70aed3ac6993b4affa87272b58348fee031bf3618"
    }
  }
]